Assay Development and Screening

To enable collaboration and scientific advancement, CDoT provides assay development services and capabilities to the wider Ó³»´«Ã½ community and its affiliates. Working alongside the CDoT Discovery Science and Translational Pharmacology groups, the team can help investigators brainstorm, develop and/or optimize their assay, in both stand-alone or automated fashion, leveraging our industry-grade equipment and capabilities. Whether the goal is to reduce assay variability, increase throughput or generate consistent, high quality data, the team is here to help. Equipment and capabilities include:
Inquiries about Assay Development can be made by emailing
CDoT-Collaborate@broadinstitute.org
High throughput screening (HTS) is the massively parallel testing of biological activity or perturbations to an assay system, typically carried out in multi-well titer plates (MTPs.) With CDoT’s 4 fully-integrated automated systems, the team can quickly screen 100s to 1,000s of compound plates per day. Working alongside the compound management and informatics group, the team can help screen, track and analyze experiments against diverse libraries selected from the Ó³»´«Ã½â€™s 800,000+ compounds (including the set).
Inquiries about HTS can be made by emailing
cdot-automation@broadinstitute.org
The High Content Imaging (HCI) facility within CDoT works with Ó³»´«Ã½â€™s principal investigators (PI) and their collaborators providing access to state-of-the-art imaging capabilities and scientific expertise to develop and execute HCI related assays to achieve scientific insight into cellular phenotypic fingerprints and complex disease models.
Currently, the platform includes two fully automated, state-of-the-art imaging systems that offer a wide range of applications which include:
In addition to the high-content image offering, the team offers comprehensive image analysis capabilities, including:
Inquiries about HCI can be made by emailing
CDoT-Collaborate@broadinstitute.org